Elawyers Elawyers
Ohio| Change

In re Zofran (Ondansetron) Products Liability Litigation, 1:15-md-2657-FDS (2019)

Court: District Court, D. Massachusetts Number: infdco20190111c67 Visitors: 6
Filed: Jan. 10, 2019
Latest Update: Jan. 10, 2019
Summary: FURTHER ORDER SUPPLEMENTING AND MODIFYING MDL ORDER NO. 25 MDL Order No. 29 F. DENNIS SAYLOR, IV , District Judge . This order supplements and modifies the terms of paragraph 7 of MDL Order No. 25 concerning motions to exclude or limit expert testimony. The motions seeking to exclude or limit expert testimony on the subjects of general causation or liability pursuant to Fed. R. Evid. 702 or Daubert v. Merrell Dow Pharmaceuticals, Inc. , 509 U.S. 579 (1993), shall follow the following
More

FURTHER ORDER SUPPLEMENTING AND MODIFYING MDL ORDER NO. 25

MDL Order No. 29

This order supplements and modifies the terms of paragraph 7 of MDL Order No. 25 concerning motions to exclude or limit expert testimony.

The motions seeking to exclude or limit expert testimony on the subjects of general causation or liability pursuant to Fed. R. Evid. 702 or Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), shall follow the following briefing schedule:

General Causation Experts

January 18, 2019 responses to opening brief(s) (not to exceed 125 pages in total per party for all experts) February 7, 2019 replies due (not to exceed 85 pages in total per party for all experts) March 5, 2019 Daubert hearing for general causation experts

Except as set forth above, MDL Order No. 25 remains in full force and effect.

So Ordered.

Source:  Leagle

Can't find what you're looking for?

Post a free question on our public forum.
Ask a Question
Search for lawyers by practice areas.
Find a Lawyer